Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Sherbrooke

$17,500.00

Structure-function study of prostaglandin F2alpha receptor (FP) biased signaling

EF 2021-22

Résumé
Preterm birth is the world's leading cause of death for children under the age of 5. Yet, there are no effective medications to safely prevent this condition. Prostaglandin F2alpha (PGF2alpha) is a bioactive lipid that plays a role in several physiological functions, including the initiation of contractions during preterm birth. To act, PGF2alpha binds and activates a G protein-coupled receptor (GPCR) named FP on the cell surface. As such, FP is a promising therapeutic target for the prevention of preterm birth. GPCRs are good therapeutic targets, but the use of drugs aiming them is often accompanied by adverse effects. Recent advances in understanding the three-dimensional structure of these receptors have led to advances in the creation of drugs with fewer side effects. We want to use this new approach to study the structure of the FP receptor and to further investigate how it transmits the physiological signal of PGF2alpha, especially during the initiation of contractions in pregnant women. As such, we want to understand which elements are important so that the future drugs prevent preterm birth with minimum adverse effects. To do this, we propose to determine the general structure of the FP, how PGF2alpha binds to the receptor, and to identify the elements of the receptor responsible for the transmission of different cellular signals. With this information, we could develop tools to identify which signals from the FP are involved in the induction of contractions. In the long term, our work could lead to the elaboration of new strategies in the development of drugs for the prevention of preterm delivery.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
467231
Name
Macovei Madalina
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Structure-function study of prostaglandin F2alpha receptor (FP) biased signaling
Programtype2
Studentship Programs
Orgnameinp2
Université de Sherbrooke
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Fp; Gpcr; Protein Purification; Signaling; Stuctual Biology; X-Ray Crystallography
Abstract
Preterm birth is the world's leading cause of death for children under the age of 5. Yet, there are no effective medications to safely prevent this condition. Prostaglandin F2alpha (PGF2alpha) is a bioactive lipid that plays a role in several physiological functions, including the initiation of contractions during preterm birth. To act, PGF2alpha binds and activates a G protein-coupled receptor (GPCR) named FP on the cell surface. As such, FP is a promising therapeutic target for the prevention of preterm birth. GPCRs are good therapeutic targets, but the use of drugs aiming them is often accompanied by adverse effects. Recent advances in understanding the three-dimensional structure of these receptors have led to advances in the creation of drugs with fewer side effects. We want to use this new approach to study the structure of the FP receptor and to further investigate how it transmits the physiological signal of PGF2alpha, especially during the initiation of contractions in pregnant women. As such, we want to understand which elements are important so that the future drugs prevent preterm birth with minimum adverse effects. To do this, we propose to determine the general structure of the FP, how PGF2alpha binds to the receptor, and to identify the elements of the receptor responsible for the transmission of different cellular signals. With this information, we could develop tools to identify which signals from the FP are involved in the induction of contractions. In the long term, our work could lead to the elaboration of new strategies in the development of drugs for the prevention of preterm delivery.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Macovei, Madalina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~